- Home
- CGTX vs TARA Comparison
CGTX vs TARA Comparison
Compare CGTX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- TARA
- Stock Information
- Founded
- CGTX 2007
- TARA N/A
- Country
- CGTX United States
- TARA United States
- Employees
- CGTX N/A
- TARA N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGTX Health Care
- TARA Health Care
- Exchange
- CGTX Nasdaq
- TARA Nasdaq
- Market Cap
- CGTX 158.8M
- TARA 165.5M
- IPO Year
- CGTX 2021
- TARA N/A
- Fundamental
- Price
- CGTX $1.66
- TARA $4.29
- Analyst Decision
- CGTX Strong Buy
- TARA Strong Buy
- Analyst Count
- CGTX 3
- TARA 6
- Target Price
- CGTX $2.83
- TARA $19.80
- AVG Volume (30 Days)
- CGTX 1.3M
- TARA 380.8K
- Earning Date
- CGTX 11-06-2025
- TARA 11-03-2025
- Dividend Yield
- CGTX N/A
- TARA N/A
- EPS Growth
- CGTX N/A
- TARA N/A
- EPS
- CGTX N/A
- TARA N/A
- Revenue
- CGTX N/A
- TARA N/A
- Revenue This Year
- CGTX N/A
- TARA N/A
- Revenue Next Year
- CGTX N/A
- TARA N/A
- P/E Ratio
- CGTX N/A
- TARA N/A
- Revenue Growth
- CGTX N/A
- TARA N/A
- 52 Week Low
- CGTX $0.22
- TARA $2.21
- 52 Week High
- CGTX $3.83
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- CGTX 48.96
- TARA 35.78
- Support Level
- CGTX $1.54
- TARA $4.96
- Resistance Level
- CGTX $1.77
- TARA $5.31
- Average True Range (ATR)
- CGTX 0.13
- TARA 0.29
- MACD
- CGTX -0.01
- TARA -0.18
- Stochastic Oscillator
- CGTX 31.49
- TARA 11.62
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).